Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Heppt MV et al (2022) Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J Clin Med 11(6):1654
2. Leiter U et al (2023) German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma”; Long version of the update 2023. EJC Skin Cancer 1:100007
3. Heppt MV et al (2023) S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma”—update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen’s disease), occupational disease and structures of care. J Dtsch Dermatol Ges 21(10):1249–1262
4. Leiter U et al (2023) S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma”—update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. J Dtsch Dermatol Ges 21(11):1422–1433
5. Kandolf L et al (2024) European consensus-based interdisciplinary guideline for diagnosis, treatment and prevention of actinic keratoses, epithelial UV-induced dysplasia and field cancerization on behalf of European Association of Dermato-Oncology, European Dermatology Forum, European Academy of Dermatology and Venereology and Union of Medical Specialists (Union Europeenne des Medecins Specialistes). J Eur Acad Dermatol Venereol 38(6):1024-1047